2021 at a glance
766 m
Patients reached
with Novartis medicines
21
Major approvals (US, EU, Japan, China)
including two new molecular entity approvals from the US Food and Drug Administration (FDA)
3
Breakthrough therapy designations
from the FDA
51.6 bn
Net sales
growing 4% in constant currencies from 2020 (USD)
16.6 bn
Core operating income
growing 6% in constant currencies from 2020 (USD)
7.4 bn
Total dividends paid
to shareholders (USD)
71 bn
Treatments supplied
through Novartis facilities
78
Employee engagement
score in Q4 (out of 100), 5 points higher than the industry benchmark
300 000
Patients using AI Nurse
our cardiovascular disease app in China
1 bn
Antimalarial treatments
delivered in the past two decades in endemic countries, more than 90% of which were supplied without profit
40 m
Doses produced
of the Pfizer-BioNTech vaccine for COVID-19
-34%
Greenhouse gas emissions
reduced vs. 2016 baseline (Scope 1 and Scope 2)
Ratings and recognition
Access to Medicine Index
Novartis ranked second in 2021, retaining our 2018 position
Dow Jones Sustainability World Index
Novartis was also included in the DJSI Europe Index
Sustainalytics
Novartis leads in the pharmaceutical subindustry group
World’s 25 Best Workplaces™
Novartis is proud to be included in Fortune’s World’s 25 Best Workplaces™ list
Bloomberg Gender-Equality Index
Novartis was included for the second year in a row